AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta's December 2023 EGM was held to approve the final tranche of the Company's $1.65m capital raise. In his address, Chair Paul MacLeman, highlights:

The value of these funds to enable progress of AdAlta's most important strategy, realising the value of lead asset AD-214 for Idiopathic Pulmonary Fibrosis by securing non-dilutive funding partnerships to progress to Phase II

The recent clinical outcomes that are helping advance those partnering discussions

CEO and Managing Director, Tim Oldham, adds his summary in the attached video

Chair address to EGM

Summary